Novex nupage mes sds running buffer

Example 11

To assess the purity and integrity of recombinant human NI-308 antibodies. In brief, human NI-308 antibodies were expressed by transient transfections of CHO-S cells and purified by protein A affinity purification on an FPLC system (ÄKTApurifier; GE Healthcare Life Sciences). After PD-10 column (GE Healthcare Life Sciences) desalting, antibodies were formulated in PBS. Five μg of purified recombinant human NI-308 antibodies were resolved under reducing conditions by gradient SDS-PAGE (Novex® Bis-Tris NuPAGE® 4-12%; Life Technologies Europe B.V., Zug, Switzerland) using Novex® NuPAGE® MES SDS Running Buffer complemented with antioxidant (Life Technologies Europe B.V., Zug, Switzerland) followed by Coomassie blue staining (Novex® SimplyBlue™ SafeStain, Life Technologies Europe B.V., Zug, Switzerland). As a result, SDS-PAGE analysis under reducing conditions of the recombinant human NI-308 antibodies revealed two major bands corresponding to the antibody heavy and light chains at the expected size. No significant contaminations or proteolytic degradation products were detectable (FIG. 13).

Example 11

To assess the purity and integrity of recombinant human NI-308 antibodies. In brief, human NI-308 antibodies were expressed by transient transfections of CHO-S cells and purified by protein A affinity purification on an FPLC system (ÄKTApurifier; GE Healthcare Life Sciences). After PD-10 column (GE Healthcare Life Sciences) desalting, antibodies were formulated in PBS. Five μg of purified recombinant human NI-308 antibodies were resolved under reducing conditions by gradient SDS-PAGE (Novex® Bis-Tris NuPAGE® 4-12%; Life Technologies Europe B.V., Zug, Switzerland) using Novex® NuPAGE® MES SDS Running Buffer complemented with antioxidant (Life Technologies Europe B.V., Zug, Switzerland) followed by Coomassie blue staining (Novex® SimplyBlue™ SafeStain, Life Technologies Europe B.V., Zug, Switzerland). As a result, SDS-PAGE analysis under reducing conditions of the recombinant human NI-308 antibodies revealed two major bands corresponding to the antibody heavy and light chains at the expected size. No significant contaminations or proteolytic degradation products were detectable (FIG. 13).